Evidence map›Paper›PMID 34849165›Full record

ArticleAsian journal of pharmaceutical sciences2021

Anti-EpCAM functionalized graphene oxide vector for tumor targeted siRNA delivery and cancer therapy.

Si Chen, Shuang Zhang, Yifan Wang, Xin Yang, Hong Yang, Chunying Cui

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian journal of pharmaceutical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. siRNA and targeted delivery systems in breast cancer therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  15. Article
  16. Review
  17. Review
  18. Novel Tumor-Targeting Nanoparticles for Cancer Treatment-A Review.International journal of molecular sciences · 2022
    Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Si ChenSchool of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.
Shuang ZhangSchool of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.
Yifan WangSchool of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.
Xin YangSchool of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.
Hong YangYanjing Medical College, Capital Medical University, Beijing 101300, China.
Chunying CuiSchool of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China.
Ministry of Education of the People's Republic of China · CNCapital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Graphene oxide (GO) has emerged as a potential drug delivery vector. For siRNA delivery, GO should be modified to endow it with gene delivery ability and targeting effect. However, the cationic materials used previously usually had greater toxicity. In this study, GO was modified with a non-toxicity cationic material (chitosan) and a tumor specific monoclonal antibody (anti-EpCAM) for the delivery of survivin-siRNA (GCE/siRNA). And the vector (GCE) prepared was proved with excellent biosafety and tumor targeting effect. The GCE exhibited superior performance in loading siRNA, maintained stability in different solutions and showed excellent protection effect for survivin-siRNA

Indexed as

Anti-EpCAMGene silencingGraphene oxidesiRNA deliverySurvivin

Identifiers

PMID34849165
PMCPMC8609427
OpenAlexW3184269199

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.